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Rationale: More than half of patients who receive thrombolysis for acute ischaemic
stroke fail to recanalize. Elucidating biological factors which predict recanalization could
identify therapeutic targets for increasing thrombolysis success.
Hypothesis: We hypothesize that individual patient plasmin potential, as measured by in
vitro response to recombinant tissue-type plasminogen activator (rt-PA), is a biomarker
of rt-PA response, and that patients with greater plasmin response are more likely to
recanalize early.
Methods: This study will use historical samples from the Barcelona Stroke Thrombolysis
Biobank, comprised of 350 pre-thrombolysis plasma samples from ischaemic stroke
patients who received serial transcranial-Doppler (TCD) measurements before and after
thrombolysis. The plasmin potential of each patient will be measured using the level
of plasmin-antiplasmin complex (PAP) generated after in-vitro addition of rt-PA. Levels
of antiplasmin, plasminogen, t-PA activity, and PAI-1 activity will also be determined.
Association between plasmin potential variables and time to recanalization [assessed on
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serial TCD using the thrombolysis in brain ischemia (TIBI) score] will be assessed using
Cox proportional hazards models, adjusted for potential confounders.
Outcomes: The primary outcomewill be time to recanalization detected by TCD (defined
as TIBI ≥4). Secondary outcomes will be recanalization within 6-h and recanalization
and/or haemorrhagic transformation at 24-h. This analysis will utilize an expanded
cohort including ∼120 patients from the Targeting Optimal Thrombolysis Outcomes
(TOTO) study.
Discussion: If association between proteolytic response to rt-PA and recanalization
is confirmed, future clinical treatment may customize thrombolytic therapy to maximize
outcomes and minimize adverse effects for individual patients.
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INTRODUCTION
Despite the increasing use of mechanical thrombectomy
(MT), thrombolysis with recombinant tissue-type plasminogen
activator (rt-PA) remains a cornerstone of acute ischaemic stroke
treatment. Upon administration, rt-PA cleaves endogenous
plasminogen (a free-floating but inactive protein) into its active
form plasminogen; using fibrin as a cofactor so that the
majority of plasmin generation occurs at the sight of a fibrinous
clot. Plasmin is rapidly bound by α2-antiplasmin to form the
inactive plasmin-antiplasmin (PAP) complex but is a potent
fibrinolytic nonetheless (1). However, more than 60% of patients
who receive rt-PA fail to recanalize (2) and this failure of
recanalization has been associated with poor patient outcomes,
even compared to patients who did not receive any reperfusion
therapy (3). While great strides have been made with regard
to selecting patients who are likely to have a favorable clinical
outcome after thrombolysis (4–6), the reasons some patients
fail to recanalize remain largely unknown. Previous studies have
examined baseline levels of individual fibrinolysis markers in
acute ischemic stroke patients (7) but this approach is limited
as the potency of thrombolysis depends on the net capacity
of a patient’s plasma to generate plasmin from plasminogen
in response to rt-PA and this may not necessarily correlate
with baseline levels of individual fibrinolysis markers. We aim
to examine association between net plasmin generation in




Blood samples were collected via venepuncture into
sodium-citrate anticoagulated vacuum-tubes during routine
pre-thrombolysis work-up. Extracted plasma was stored at
−80◦C until analyzed.
Inclusion and Exclusion Criteria
Samples from patients who received thrombolysis and underwent
transcranial doppler (TCD) before thrombolysis, and at least
once within 6 h after thrombolysis will be included in the
primary analysis. In addition, samples from patients who
received thrombolysis and underwent angiography, either
computed tomography (CT) or magnetic resonance imaging
(MRI), before and 24-h post-thrombolysis will be included in
secondary analyses.
Plasmin Assays (Lab Work)
Pre-thrombolysis plasma samples will be analyzed for both
baseline fibrinolytic markers and ex-vivo plasmin generating
capacity using different modalities.
All samples will be tested for baseline total plasminogen,
α2-antiplasmin, plasminogen activator inhibitor-1 (PAI-1)
levels, and baseline t-PA activity using specific enzyme-
linked immunosorbent assays (ELISA) from Molecular
Innovations, USA.
Plasmin-antiplasmin (PAP) complexes will be measured as
a surrogate for rt-PA inducible plasmin activity generated after
addition of rt-PA. To achieve this, PAP complexes will be
measured at baseline and also after the ex-vivo addition of 50 nM
rt-PA (“Inducible PAP”) in the presence and absence of a soluble
fibrin co-factor, Cyanogen bromide activated Fibrinogen (CNBr-
Fib, 0.25 mg/ml) Both ELISA kit and CNBr-Fib used for the PAP
analysis are from DRG International (USA).
Inducible PAP levels will be measured following stimulation
of the plasma samples with vehicle (for baseline levels), addition
of CNBr-Fib alone, rt-PA alone, and both rt-PA + CNBr-Fib
for 10min at 37◦C and the reaction stopped by combining
with aprotinin (20µM), a serine protease inhibitor which
competitively inhibits plasmin. The generated PAP complexes
will then be quantified using a commercial ELISA (DRG
International, USA). Treatment of samples with cofactor alone
is to determine whether plasma is able to generate a significant
amount of inducible PAP on its own, due to elevated levels of
endogenous t-PA that may occur during acute ischaemic stroke.
Furthermore, the rate of plasmin generation within each
sample will also be evaluated with an amidolytic assay using
S2251, a chromogenic substrate specific for plasmin (8). The
production of plasmin within the sample hydrolyses S-2251,
liberating a pNA chromogenic group detected on a plate reader
at an absorbance wavelength of 405 nm.
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FIGURE 1 | Sample and data collection timeline from patient arrival at hospital.
PAP complex levels will also be determined in plasma samples
obtained at various time points post-rt-PA thrombolysis (1,
2, 12, and 24 h). Hence the degree of rt-PA inducible PAP
complexes determined in the pre-thrombolysis samples will then
be correlated to the actual degree of PAP complexes formed in
vivo after rt-PA administration. This will also provide relevant
information as to the temporal nature of the response to rt-
PA treatment.
Imaging/Recanalization Assessment
Patients in the primary analysis received non-contrast computed
tomography (NCCT) to rule out hemorrhage and TCD pre-
thrombolysis and at 1, 2, 6, and 24-h post-thrombolysis (see
Figure 1). The initial occlusion and subsequent recanalization
were assessed using the TIBI score. For the purposes of this
analysis a TIBI score ≥4 will be considered as recanalization.
Statistical Analysis
The primary analysis will use Cox proportional hazards
regression to estimate the relationship between plasmin potential








variables and time to recanalization, defined by a thrombolysis in
brain ischemia (TIBI) score of 4 or 5 (9).
The key predictive variables will be the fibrinolytic potential,
as measured by the in vitro response to thrombolytic agent.
This response will be measured in terms of the amount of
PAP formed, the ratio of formed PAP to baseline PAP or the
rate of plasmin activity. The Kaplan-Meier survival function
for various levels of the key predictors will be visualized and
a Cox Proportional-Hazard regression will be used to estimate
the hazard ratio with 95% confidence intervals for the effect
of each key predictor on time to recanalization after adjusting
for potential confounders. Potential confounders include blood
glucose level, initial occlusion size (as measured by baseline
TIBI), age, sex, prior medications, and chronic illness. The
proportional hazards assumption will be tested using standard
statistical tests and residual plots. Predictive accuracy will be
quantified using c-statistics.
Secondary analyses will use logistic regressions to examine
the correlations between fibrinolytic markers and recanalization
within 6 h and outcome at 24-h post-thrombolysis, recanalization
and haemorrhagic transformation of cerebral infarcts detected
on follow-up CT and disability at 3 months as measured by the
modified Rankin scale.
Available Sample Size
The Barcelona Stroke Thrombolysis Biobank consists of samples
from a total 350 patients who underwent TCD before
thrombolysis and NCCT before and 24-h after thrombolysis, 332
of whom underwent TCD at least once after thrombolysis (see
Table 1). The TOTO (10) sample is forecast to contain samples
from ∼250 patients by the time analysis is conducted, ∼120 of
these patients will have vessel occlusions visible on CTA or MRA.
The sample size available for the primary recanalization
analysis will consist of the 332 patients from the Barcelona
Stroke Thrombolysis Biobank who underwent at least 1 post-
thrombolysis TCD (11). Initially 50% of these samples will
be analyzed in a pilot study. If a larger sample is required,
this pilot study will allow for formal power calculations to
determine the final sample size. The sample size for the logistic
regression analysis of recanalization at 24-h will be ∼450
including Barcelona Stroke Thrombolysis Biobank samples and
those from the TOTO study with clear vessel occlusions. Analysis
of haemorrhagic transformation will include all 600 samples
(350 from the Barcelona Stroke Thrombolysis Biobank and 250
from TOTO).
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DISCUSSION
Individual variation in fibrinolytic potential remain
poorly understood, especially with regard to its effects on
clinical outcomes after thrombolysis. The Barcelona Stroke
Thrombolysis Biobank provides an exceptional sample in
which to examine correlations between fibrinolytic markers and
recanalization as the use of serial TCD assessments allows direct
assessment of early recanalization, and being collected before
mechanical thrombectomy was common practice, the biobank
consists entirely of patients who received thrombolysis only.
Where subsequent biobank studies such as TOTO have collected
much more detailed baseline data in the form of multi-modal
CT, such examinations cannot be repeated as often as TCD so
these studies lack the timing data available from the Barcelona
Stroke Thrombolysis Biobank. In addition, the Barcelona Stroke
Thrombolysis Biobank recruited patients between 2003 and
2009, before the widespread use of mechanical thrombectomy
and was therefore purely focussed on thrombolysis. Subsequent
biobanks (including TOTO) have been forced to either recruit
patients who undergo mechanical thrombectomy, or recruit
fewer patients with large-vessel occlusions.
If individual fibrinolytic potential does correlate with time
to recanalization, future studies could focus on reducing
variation in fibrinolytic potential, for example by supplementing
plasminogen in patients before thrombolysis.
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